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Deregulated hedgehog pathway 
signaling is inhibited by the 
smoothened antagonist LDE225 
(Sonidegib) in chronic phase chronic 
myeloid leukaemia
David A. Irvine1,*, Bin Zhang2,*, Ross Kinstrie1, Anuradha Tarafdar1, Heather Morrison1, 
Victoria L. Campbell1, Hothri A. Moka1, Yinwei Ho2, Colin Nixon4, Paul W. Manley3, 
Helen Wheadon1, John R. Goodlad5, Tessa L. Holyoake1, Ravi Bhatia6 & Mhairi Copland1
Targeting the Hedgehog (Hh) pathway represents a potential leukaemia stem cell (LSC)-directed 
therapy which may compliment tyrosine kinase inhibitors (TKIs) to eradicate LSC in chronic phase 
(CP) chronic myeloid leukaemia (CML). We set out to elucidate the role of Hh signaling in CP-CML and 
determine if inhibition of Hh signaling, through inhibition of smoothened (SMO), was an effective 
strategy to target CP-CML LSC. Assessment of Hh pathway gene and protein expression demonstrated 
that the Hh pathway is activated in CD34+ CP-CML stem/progenitor cells. LDE225 (Sonidegib), a 
small molecule, clinically investigated SMO inhibitor, used alone and in combination with nilotinib, 
inhibited the Hh pathway in CD34+ CP-CML cells, reducing the number and self-renewal capacity of 
CML LSC in vitro. The combination had no effect on normal haemopoietic stem cells. When combined, 
LDE225 + nilotinib reduced CD34+ CP-CML cell engraftment in NSG mice and, upon administration 
to EGFP+ /SCLtTA/TRE-BCR-ABL mice, the combination enhanced survival with reduced leukaemia 
development in secondary transplant recipients. In conclusion, the Hh pathway is deregulated in 
CML stem and progenitor cells. We identify Hh pathway inhibition, in combination with nilotinib, as a 
potentially effective therapeutic strategy to improve responses in CP-CML by targeting both stem and 
progenitor cells.
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterised by massive myeloid 
expansion, accumulation of differentiating granulocytic precursors and terminally differentiated effector cells 
leading to the key clinical features at presentation of marked peripheral blood granulocytosis, basophilia, sple-
nomegaly and often thrombocytosis and anaemia1. Untreated, the clinical course of CML is one of inevitable 
progression from a stable chronic phase (CP) lasting about 5 years from diagnosis, where there is gradual accu-
mulation of leukaemic myeloid progenitors, to accelerated phase characterised by accumulation and clonal evolu-
tion of increasingly primitive myeloid precursors in the blood or bone marrow (BM) before terminating in a blast 
crisis (BC) with rapid accumulation of immature myeloid or lymphoid precursors resembling acute leukaemia.
In optimally responding CP-CML patients, the majority have molecular evidence of persisting disease after 
prolonged tyrosine kinase inhibitor (TKI) therapy2,3. Furthermore, of those patients who achieve sustained 
molecularly undetectable leukaemia and discontinue TKI treatment the majority suffer molecular relapse4–7. One 
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reason for disease persistence despite prolonged TKI therapy is that, while harbouring the BCR-ABL fusion pro-
tein, leukaemic stem cells (LSC) are resistant to pharmacologically achievable concentrations of TKI8–10. Evidence 
is now emerging to suggest that CML LSC may not be dependent on BCR-ABL kinase signaling for survival11–13. 
Therefore, in order to eradicate the leukaemic clone and cure CML, it is likely that alternative strategies specif-
ically targeting the CML LSC population alone or in combination with conventional TKI will be required, thus 
achieving synthetic lethality through the abrogation of other critical survival pathways14.
One of the major pathways influencing stem cell self-renewal is the hedgehog (Hh) signaling pathway15–17. 
In embryogenesis, this pathway is critically involved in patterning but remains active in adult tissue where it 
contributes to tissue homeostasis, regeneration and healing18. There is accumulating evidence that Hh signaling 
plays a critical role in the pathogenesis of various haemopoietic malignancies19–23. Particular interest has focused 
on the role of Hh signaling in CML. Studies have shown that Hh signaling is increased in BCR-ABL+ progenitor 
cells and Hh signaling is further upregulated with disease progression24–27. Dierks et al. demonstrated that Hh 
signaling is upregulated in a pMSCV/Bcr-Abl/IRES-GFP retroviral vector murine model of CML and in their 
patient cohort, which was predominantly comprised of BC-CML, through upregulation of Smoothened (SMO)27. 
Experiments using murine models of CML have demonstrated that Smo deletion or pharmacological inhibition 
results in reduced LSC and a greatly reduced capacity to recrudesce the disease in secondary hosts24,27. The com-
bination of standard TKI therapy with the naturally occurring SMO inhibitor cyclopamine resulted in the largest 
reduction in LSC in vitro and in vivo in murine experiments24,27. Therefore Hh signaling is active in murine mod-
els of CML and is critical to the maintenance and expansion of the disease clone in BC-CML.
LDE225 (Sonidegib; Novartis Pharma) is a synthetic, highly potent and selective, small molecule clinical SMO 
inhibitor resulting from the optimisation of a hit arising from a high throughput screening phenotypic assay 
designed to identify SMO inhibitors. LDE225 interacts directly with SMO, in a similar fashion to cyclopamine, to 
reduce expression of downstream Hh signaling targets28. LDE225 is effective in various Hh-dependent tumour 
models and inhibits downstream expression of Hh targets in cell lines, in vivo animal models and in patients, and 
is currently under clinical trial investigation both as a single agent29 and in combination (reviewed in30).
It is not clear to what extent Hh signaling is relevant in CP-CML, where stem cell-directed therapy might 
arguably be more effective in achieving disease eradication. Therefore, we set out to further define the role of 
Hh signaling in CP-CML and determine if inhibition of Hh signaling, most easily achieved through inhibition 
of SMO, using the SMO inhibitor LDE225 was an effective strategy to target CP-CML LSC. Using a combination 
of in vitro stem cell assays and in vivo murine models, this is the first study to robustly report efficacy for a SMO 
inhibitor, as a single agent, or in combination with a TKI, in models of CP-CML.
Results
The Hh pathway is expressed and active in LSCs in an in vivo murine model of CP-CML and 
in primary patient-derived CP-CML LSCs. Quantitative RT-PCR was performed to assess the relative 
gene expression of components of the Hh signaling pathway in the bone marrow (BM) of the CP-CML murine 
model Scl-tTa-BCR-ABL31. BM long-term haemopoietic stem cells (LTHSC) showed increased expression of Hh 
target genes Gli1, Ptch1 and Ptch2 (all p < 0.05), compared to control (Fig. 1A). Gli2 expression was unchanged. 
Similarly, Scl-tTa-BCR-ABL BM multipotent progenitors (MPP) showed increased expression of the Hh target 
gene Gli1 (p < 0.05). In contrast stromal cells isolated from murine CP-CML BM demonstrated reduced expres-
sion of Ptch1 with no change in Gli1 expression. Additionally other Hh targets such as Cdc2 and CcnB1 were also 
increased in CML LTHSC and MPP (data not shown). No difference in expression of Ihh expression was seen 
between CML and normal BM cells. Dhh and Shh were not detected (data not shown).
To better understand alterations in Hh signaling in primary human CML stem and progenitor cell popu-
lations, we sorted primary CP-CML or normal CD34+ cells into pure haemopoietic stem cell (HSC/LSC; 
lin−CD34+CD38−CD90+), common myeloid progenitor (CMP; lin−CD34+CD38+CD123+CD45RA−), 
granulocyte-macrophage progenitor (GMP; lin−CD34+CD38+CD123+CD45RA+) and megakaryocyte-erythroid 
progenitor (MEP; lin−CD34+CD38+CD123−CD45RA−) subpopulations by FACS. Each subpopulation was ana-
lysed by dual-fusion FISH (D-FISH) for the presence of the Philadelphia (Ph) chromosome and scored. Virtually 
all cells of all subpopulations in CP-CML were Ph+ by D-FISH analysis (Supplementary Table 1). There was no 
significant difference between subpopulations from individual patients. Greater than 87% of HSCs in all patients 
were Ph+, confirming that the translocation arises in the most primitive haemopoietic cells that can be isolated by 
surface phenotype, and is the dominant clone in all myeloid progenitor subpopulations. Furthermore, we assessed 
BCR-ABL gene expression in the different stem and progenitor cell populations and confirmed increased expres-
sion of BCR-ABL mRNA in the CP-CML LSC population relative to the other subpopulations (Supplementary 
Figure 1).
Gene expression of Hh pathway mediators and downstream targets was assessed in HSC, CMP, GMP and 
MEP subpopulations from CP-CML compared with normal samples (Fig. 1B–D). There was altered expression of 
several key regulators and targets of Hh signaling in CML LSC versus normal HSC. Most prominently we noted 
reduction in expression of the Hh pathway inhibitors GLI3 and SUFU (both p < 0.05; Fig. 1B) in CP-CML LSC 
compared to normal HSC. We also observed up-regulation of downstream targets CCNB2, STIL and FOXM1 (all 
p < 0.05; Fig. 1C) in CP-CML LSC. There was a trend for up-regulation of GLI1 in CP-CML LSC, but this did 
not reach statistical significance (p = 0.1). In addition, higher levels of GLI1 were maintained in primitive CML 
progenitors (CMP and GMP) compared to normal. There was no alteration in expression of SMO either between 
CP-CML and normal tissue or between haemopoietic progenitor subpopulations (Fig. 1D).
Thus, at the mRNA level, critical downstream targets and mediators involved in Hh signaling are deregulated 
in CP-CML both in the Scl-tTa-BCR-ABL murine model of CP-CML and in primitive CP-CML HSC derived from 
primary patient samples.
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To demonstrate Hh pathway protein expression and activity, immunohistochemistry (IHC) for ligands SHH, 
IHH and DHH was performed on BM trephines from CML patients and healthy individuals. There was no signif-
icant difference in expression of SHH or DHH between CML and healthy subjects (Fig. 2A). Interestingly, SHH 
showed both nuclear and cytoplasmic staining within trephine samples (Fig. 2B). A nuclear expression pattern 
has been previously described in subsets of cells in the CNS32. IHH was modestly increased in CP-CML (p < 0.05; 
Fig. 2A); DHH was not expressed.
In order to determine if SMO is a potential therapeutic target it was vital to determine if haemopoietic cells 
had the machinery, i.e. primary cilia, to enable canonical Hh signaling. Unmanipulated confocal images of BM 
trephines from both normal controls and CP-CML clearly show cilia to be present (Fig. 2C). Presence of primary 
cilia was at a low frequency in both the normal (n = 10) and CML (n = 10) samples. This is the first description 
of the presence of cilia within haemopoietic tissue and provides evidence that these cells are capable of canonical 
Hh signaling which may be targeted by SMO inhibition.
Thus, quantitative RT-PCR of CP-CML LSC from both a murine model and primary patient samples, and 
immunohistochemistry/immunofluorescence of primary human BM samples provide robust evidence for Hh 
pathway de-regulation in CP-CML and a rationale for exploring the efficacy of the clinically relevant SMO antag-
onist LDE225 as a Hh pathway inhibitor in CP-CML.
The small molecule SMO antagonist LDE225 inhibits downstream Hh signaling in vivo in a 
CP-CML murine model and in primary CD34+ CP-CML cells. Studies have demonstrated that LDE225 
has a low nM IC50 in cell lines28. Based on previous studies indicating that GLI1 is an appropriate biomarker for 
Hh pathway activity33,34 and our own data showing up-regulation of GLI1 in both primary human and murine 
CP-CML LSC, we sought to assess the effect of SMO inhibition with LDE225 on GLI1 expression in CP-CML cells. 
In vivo treatment of Scl-tTa-BCR-ABL mice with LDE225 ± nilotinib resulted in inhibition of Gli1 in CP-CML 
BM LTHSC (Fig. 3A). Treatment with nilotinib alone did not affect Hh-related genes, except cell cycle-related 
genes which may be the result of BCR-ABL inhibition (data not shown). The combination of LDE225 + nilotinib 
Figure 1. The Hh pathway is expressed and active in LSCs in an in vivo murine model of CP-CML and in 
primary patient-derived CP-CML LSCs. (A) Expression of Hh pathway genes Gli1, Gli2, Ptch1 and Ptch2 in 
total BM cells, BM MPP and LTHSC subpopulations, and in BM stromal cells from wild type (non-leukaemic; 
NL) and Bcr-Abl-expressing mice (n = 6–8 mice per arm). (B–D) Gene expression in sorted subpopulations 
(HSC, CMP, GMP and MEP) from human CD34+ haemopoietic cells from CP-CML patients (n = 6) at 
diagnosis compared with normal subpopulations (n = 3). Relative gene expression of (B) Hh pathway inhibitory 
molecules GLI3 and SUFU; (C) downstream targets GLI1, CCNB2, FOXM1 and STIL; and (D) positive Hh 
pathway regulator SMO. Results represent the mean ± SEM for multiple samples normalised to B2m (murine) 
and GAPDH and HRPT1 (human); and are expressed as 2−ΔCt. Significance values; *p < 0.05.
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did not significantly increase inhibition of Gli-1 (Fig. 3A) or other Hh-related genes compared to LDE225 alone 
(data not shown).
Primary CD34+ CP-CML cells were cultured in serum free media (SFM) ± LDE225 for 6, 24 and 72 hours (h). 
No alterations in GLI1 were seen at 6 and 24 h (data not shown). At 72 h, while there was variability between the 
biological samples, GLI1 was significantly downregulated following exposure to LDE225 (10 nM; 0.78-fold and 
100 nM; 0.73-fold, respectively (p < 0.01; Fig. 3B).
To provide independent confirmation of the effect of SMO inhibition in CP-CML, lentiviral-mediated shRNA 
knockdown (KD) of SMO in primary CD34+ CP-CML cells was performed. Three independent primary CD34+ 
CML samples were transduced with a lentiviral vector expressing GFP and either SMO targeted shRNA or a 
scrambled control. Selection was based on GFP expression (Fig. 3C). The reduction in expression of SMO was 
modest in primary samples (mean 68% of control; p < 0.05; Fig. 3Di). Nevertheless, clear reduction in expression 
of GLI1 was seen in all three samples (mean 3% of control; p < 0.005; Fig. 3Dii). Additionally, a trend towards 
increased expression of GLI3 was seen (Fig. 3Diii).
Thus, pharmacologic (LDE225) or genetic inhibition (shRNA KD) of SMO leads to reduced expression of 
GLI1, a key target of Hh signaling, in primary CD34+ CP-CML cells and in a murine model of CP-CML.
Inhibition of Hh signaling with LDE225 significantly reduces colony forming cell (CFC) 
re-plating efficiency of primitive human CP-CML cells. LDE225 does not induce pro-apoptotic or 
anti-proliferative effects on primary CD34+ CP-CML cells in short term in vitro culture (Supplementary Figure 2). 
To examine the behaviour of CP-CML cells following exposure to LDE225 in greater depth, we explored whether 
LDE225 affected primary colony formation and re-plating efficiency. Primary CD34+ CP-CML cells were cul-
tured in SFM alone or in the presence of incremental concentrations of LDE225 ± nilotinib for 72 h. Following 
this, the cells were thoroughly washed to remove any remaining drug, inoculated into CFC assays and colonies 
assessed after 14 days (d). Increasing concentrations of LDE225 did not alter the size, number or type (GEMM, 
GM, CFU/BFU-E) of primary colonies formed (Fig. 4A).
To determine whether self-renewal behaviour had been altered by exposure to LDE225, we assessed secondary 
re-plating capacity of these colonies. We noted a significant reduction in re-plating capacity with increasing con-
centrations of LDE225 (p < 0.05) alone and in combination with nilotinib 5 μ M (p < 0.01; Fig. 4B,C).
Thus LDE225, alone or in combination with nilotinib, did not affect primary colony formation but reduced 
secondary re-plating capacity, a measure of self-renewal activity in haemopoietic cells.
LDE225 significantly reduces long-term culture-initiating cell (LTC-IC) frequency in 
CP-CML. Primary CD34+ CP-CML cells or normal CD34+ haemopoietic cells were incubated in SFM 
with LDE225 10 nM ± nilotinib 5 μ M for 72 h, washed and inoculated into a pre-prepared stromal co-culture. 
Compared with the untreated control, LDE225 resulted in lower LTC-IC recovery (p < 0.05; Fig. 5A). As previ-
ously shown with imatinib and dasatinib35, nilotinib demonstrated an enrichment of LTC-IC. Importantly, the 
addition of LDE225 to nilotinib led to a significant reduction in LTC-IC frequency relative to nilotinib alone, 
completely reversing the increase in LTC-IC seen with nilotinib (p < 0.05). Normal CD34+ haemopoietic cells 
demonstrated no alteration of LTC-IC abundance with LDE225, nilotinib or both relative to the untreated control 
(Fig. 5B).
Figure 2. The Hh pathway is expressed at the protein level in human haemopoietic cells with the machinery 
(i.e. primary cilia) to enable canonical Hh signaling. (A) Percentage of SHH, DHH and IHH positive cells 
per bone marrow trephine (BMT) specimen in CP-CML (n = 7) compared to normal (n = 5). Results represent 
the mean ± SEM for multiple samples. Significance values; *p < 0.05. (B) Examples of BM trephine staining of 
SHH by immunohistochemistry. (C) Example of confocal images of primary cilia from BM trephine samples 
comparing CP-CML (n = 10) to normal controls (n = 10). There was no significant difference in the number of 
primary cilia observed between normal and CP-CML BM haemopoietic cells. Scale bar 100 μ M in all images. 
Arrows highlight primary cilia demonstrated by co-localisation of α - and γ -tubulin.
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Figure 3. Pharmacologic and lentiviral SMO inhibition inhibits downstream Hh signaling in CP-CML 
cells. (A) Expression of Gli1 in total BM cells, BM MPP and LTHSC subpopulations, and in BM stromal cells 
from Bcr-Abl-expressing mice (n = 8 per arm) treated with LDE225, nilotinib, LDE225 + nilotinib or vehicle 
alone for 5 days. Results represent the mean ± SEM for multiple samples. (B) Expression of GLI1 following 72h 
exposure to LDE225 in CD34+ CP-CML cells (n = 7). Results represent the mean ± SEM for multiple samples. 
(C,D) Expression of targets and mediators of Hh signaling in CD34+ CP-CML cells following shRNA mediated 
SMO KD; (C) Representative flow cytometry histogram demonstrating comparative transfection efficiency 
of lentiviral vector containing GFP-SMO KD shRNA or GFP-Scram shRNA compared to untransfected cells. 
(D) Expression of SMO (Di), GLI1 (Dii) and the Hh pathway inhibitor GLI3 (Diii) in CD34+ CP-CML cells 
following shRNA mediated SMO KD normalised to GAPDH and compared to the scrambled control. Results 
shown represent the mean ± SEM for 3 independent transfections of different CD34+ CP-CML samples. 
Significance values; *p < 0.05; **p < 0.01; ***p < 0.005.
Figure 4. LDE225 alone or in combination with nilotinib reduces re-plating capacity of CD34+ CP-CML 
cells. (A) Relative CFC frequencies in each of the treatment arms normalized to an untreated control. Total 
number of secondary colonies formed at first re-plate from cells exposed to (B) escalating concentrations of 
LDE225 or (C) LDE225 10 nM, nilotinib 5 μ M or both (combination), normalized to an untreated control. The 
results represent the mean ± SEM; n = 5. Significance values; *p < 0.05; **p < 0.01.
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Stem cell fate decisions are formulated in the context of complex micro-environmental conditions and signal-
ing cascades36. In order to investigate the effect of long-term exposure to LDE225 ± nilotinib on CP-CML within 
a more complex microenvironment, we performed in vitro stromal co-culture in which CD34+ CP-CML cells 
were directly inoculated into supportive stromal co-cultures with incremental concentrations of LDE225 (10–
100 nM) ± nilotinib 1 μ M added to the stromal co-culture media. There was a significant reduction in LTC-IC 
numbers in the LDE225 arms (p < 0.05-p < 0.01) (Supplementary Figure 3A). Additionally, 5 weeks of contin-
ual exposure to nilotinib did not eradicate the LTC-IC population (28% of the untreated control remaining). 
Interestingly, in the experimental arms containing the combination of LDE225 + nilotinib, there was a trend to 
further reduction in the LTC-IC recovery suggesting that LDE225 targets a population of TKI-insensitive CP-CML 
cells or exerts additional anti-leukaemic effects by disruption of the microenvironment, although this was not evi-
dent microscopically with the stromal cell layers remaining intact throughout culture. (Supplementary Figure 3B).
Thus LDE225 alone or in combination with nilotinib reduced the primitive leukaemic population as measured 
by LTC-IC and reduced self-renewal activity as evidenced by re-plating capacity, suggesting that SMO inhibition 
targets the TKI-insensitive primitive stem/progenitor cell population in CP-CML.
Effect of LDE225 in combination with nilotinib on human CML LSC capable of engrafting immu-
nodeficient mice. We tested the effect of LDE225 ± nilotinib on CD34+ CP-CML and normal cells capa-
ble of engraftment in NSG mice (Fig. 6A). We observed reduced engraftment of human CP-CML CD45+ cells 
treated with the combination of LDE225 + nilotinib compared with untreated or single treatment arms (Fig. 6B). 
Human CD45+ CD34+ cells and CFC were also reduced in the marrow of mice receiving cells treated with 
LDE225 + nilotinib compared with untreated, single agent LDE225 or nilotinib (Fig. 6C,D). qRT-PCR analysis 
confirmed that BCR-ABL+ LSC contributed to engraftment in all experimental arms, and BCR-ABL mRNA levels 
were reduced in CD45+ cells obtained from the BM of mice receiving CML cells treated with the combination of 
LDE225 + nilotinib, compared with untreated or single agent LDE225 (Fig. 6E). FISH analysis showed a signifi-
cantly reduced proportion of BCR-ABL+ human cells engrafted in mice receiving cells treated with the combina-
tion of LDE225 + nilotinib compared to untreated controls and single agent arms (*p < 0.05; **p < 0.01; Fig. 6F). 
Cord blood CD34+ cells did not show changes in engraftment following treatment with nilotinib, LDE225 or 
LDE225 + nilotinib (Supplementary Figure 4). These results show that LDE225 + nilotinib selectively targets 
primitive CP-CML cells capable of in vivo engraftment.
Effect of in vivo treatment with LDE225 in combination with nilotinib on LSC in a transgenic 
BCR-ABL mouse model of CML. Low levels of engraftment of CD34+ CP-CML cells in the NSG mouse 
model limit its utility for in vivo drug treatment studies. Therefore we utilised the transgenic Scl-tTa-BCR-ABL 
mouse model31 to investigate the effect of in vivo treatment with LDE225 ±  nilotinib on CP-CML LSC (Fig. 7A,B).
There was no difference in the weight of the nilotinib or combination treated mice compared with the 
untreated cohort, however there was a small, non-significant incremental reduction in mean weight in the cohort 
treated with LDE225 alone over the 3 week treatment period (Supplementary Figure 5). Nilotinib alone resulted 
in a reduction of splenic GMP and CMP, but not LTHSC (Supplementary Figure 6Ai–iii). Single agent LDE225 
reduced splenic LTHSC, but did not significantly reduce GMP and CMP. LDE225 +  nilotinib significantly 
reduced GMP, CMP and LTHSC in the spleen. In contrast, in the BM of mice treated with LDE225, nilotinib or 
the combination, there were no significant changes in the numbers of GMP, CMP and LTHSC (Supplementary 
Figure 6Bi–iii).
Figure 5. LDE225 alone or in combination with nilotinib significantly reduces LTC-IC numbers 
in primary CD34+ CP-CML samples. LTC-IC from (A) CD34+ CP-CML cells (n = 5) and (B) normal 
CD34+ haemopoietic cells (n = 3) were cultured in the presence of LDE225 10nM, nilotinib 5μ M or both 
(combination). The results shown represent the mean ± SEM normalised to an untreated control. Significance 
values; *p < 0.05.
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A subset of mice were followed after completion of treatment, and survival off treatment was monitored for 
120d (Fig. 7C). Control mice that survived the 3 week treatment period died within a further 16d. Improved sur-
vival after discontinuation of treatment was seen in mice treated with nilotinib (median survival 40d), and further 
trend towards increased survival was shown in mice treated with the combination of LDE225 +  nilotinib (median 
survival 52d) (no treatment versus combination p < 0.01; nilotinib versus combination p = 0.15).
Bone marrow cells and spleen cells from a subset of treated mice were transplanted into secondary recipi-
ent mice. Transplantation of either BM or spleen cells from mice treated with LDE225 + nilotinib resulted in 
reduced WCC and reduced leukaemia development in secondary recipients compared to LDE225 or nilotinib 
alone (Fig. 7D). These results suggest that the combination of LDE225 + nilotinib reduces the number of BM and 
splenic LSC capable of engraftment in secondary recipients and causing disease relapse. Since the numbers of 
phenotypically identifiable BM LTHSC were not reduced after LDE225 treatment (Supplementary Figure 6Biii), 
these results suggest that LDE225 treatment results in reduced LTHSC self-renewal or engraftment potential.
Discussion
There have been major advances in the treatment of CML in recent years with the development of imatinib37 and, 
more recently, dasatinib38, nilotinib39, bosutinib40 and ponatinib41. These newer compounds target the majority of 
imatinib-resistant mutations and, in the case of dasatinib, reach further into the LSC compartment9,10. However, 
despite increasingly potent inhibition of BCR-ABL, quiescent CML LSC remain insensitive to these compounds. 
Figure 6. Combination of LDE225 + nilotinib reduces CML LSC capable of engrafting NSG mice. (A) 
NSG mice received CD34+ cells from CML patients (2 × 106 cells per mouse) cultured for 72h in the presence 
of LDE225 (10nM), nilotinib (5μ M), combination (10nM LDE225 + 5μ M nilotinib) or vehicle alone (no drug 
control) by tail vein injection. Mice were euthanized after 6 weeks and marrow contents of femurs, spleen cells 
and blood cells were obtained. The percentage of human (B) CD45+ cells and (C) CD45+ CD34+ cells engrafted 
in the BM. (D) CFC frequencies within human CD45+ cells isolated from the BM of mice and grown in 
methylcellulose progenitor assays. (E) BCR-ABL mRNA levels in BM cells obtained from mice at 6 weeks post-
transplantation (normalised to BCR mRNA levels). (F) The percentage of CD45+ BCR-ABL+ cells measured by 
FISH in BM cells obtained from mice at 6 weeks post-transplantation. Results shown represent the mean ± SEM 
for multiple samples. Significance values; *p < 0.05; **p < 0.01; n = 6–8 mice per treatment arm.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:25476 | DOI: 10.1038/srep25476
Thus, there is mounting evidence that strategies to target both quiescent LSC and proliferating cells are required 
to eradicate CML2,6–8,10,42,43.
Chronic myeloid leukaemia LSC may not be dependent on BCR-ABL kinase signaling for survival11,13. 
Therefore, in the majority of patients, it is unlikely that the CML LSC can be completely eradicated through the 
use of BCR-ABL kinase inhibitors alone. This hypothesis is further supported by observations from our group 
and others that BCR-ABL-targeted therapies such as imatinib, dasatinib or nilotinib fail to eradicate CML LSC 
in vitro8–10,42.
Our data, along with those of Radich et al.26, Dierks et al.27, Zhao et al.24, Alonso-Dominguez et al.44 and 
Sadarangani et al.45 show that the Hh pathway is a relevant therapeutic target in CML. Radich et al. demonstrated 
that the effector of Hh signaling, GLI2, was upregulated, at least at the mRNA level, with disease progression from 
CP to BC26. Similar findings have also recently been reported in acute myeloid leukaemia by Wellbrock et al. 
with high levels of GLI1 or GLI2 identified as negative prognostic markers and direct inhibition of GLI1/2 exert-
ing antileukaemic effects34. In our studies, increased GLI1 expression was seen in CP-CML LSC and there was 
retention of higher levels of GLI1 in primitive progenitor populations (CMP, GMP) compared to normal. GLI1 is 
widely utilised as a reporter of Hh activity as it is regulated at the gene expression level and expression is respon-
sive to Hh signaling46. We found expression of GLI2 to be at the limits of detection in both normal HSC and 
CP-CML LSC cells (data not shown). Alonso-Dominguez et al. provided evidence that high PTCH1 expression in 
mononuclear cells at diagnosis predicts imatinib failure in CP-CML and identifies a cohort of patients that may 
benefit from a second generation TKI as first-line therapy44. Our data demonstrated that Ptch1 and Ptch2 were 
significantly increased in murine LTHSC (Fig. 1A) and there was a trend for increased PTCH1 in CML LSC (data 
not shown), however this did not predict imatinib failure. These discrepant results may be due to the different cell 
populations analysed (CP-CML LSC versus mononuclear cells).
The presented results indicate that the main negative regulators of Hh signalling, GLI3 and SUFU are downreg-
ulated with degree of maturity in normal haemopoiesis, but stably expressed at a low level in CP-CML (Fig. 1B). 
We saw no difference in expression of SMO across subpopulations (Fig. 1D). These are intriguing results; the lack 
of difference in expression of the key positive regulator of Hh signalling SMO is in contrast with Dierks et al. who 
demonstrated that Smo expression was upregulated at the RNA and protein level in murine BCR-ABL+ cells27, 
providing a possible mechanism for Hh over activity in CML cells. Our results hint toward an alternative, cell 
autonomous mechanism of activation relating to reduced expression of key negative regulatory elements. When 
Figure 7. LDE225 + nilotinib administration significantly reduces leukaemia stem and progenitor cells 
in the spleen of BCR-ABL expressing mice. (A) Schema for experiments using the EGFP+ /SCLtTA/TRE-
BCR-ABL mouse model to assess drug efficacy in vivo. (B) Representative FACS plot for LSK and LTHSC 
cells. (C) Survival of mice after discontinuation of treatment. (D) Results of transplantation of BM and spleen 
cells obtained after treatment (cells pooled from 8 mice, 5 × 106 cells injected per recipient mouse, 8 mice per 
condition for both BM and spleen cells) into wild-type (wt) FVB/N mice. WCC and engraftment was monitored 
by drawing PB every 4 weeks. The fraction of recipient mice showing evidence of leukemia within 16 weeks after 
secondary transplantation was shown for (i) BM cells and (ii) spleen cells. Results represent the mean ± SEM for 
multiple samples. Significance values; *p < 0.05; **p < 0.01; n = 8.
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SUFU and GLI3 are downregulated, the result would likely be to make a cell more sensitive to Hh signalling and 
the production of a stronger and more prolonged response47. This would require further work to confirm differ-
ential expression at the protein level but is an area of great mechanistic interest. Expression of several other targets 
of Hh signaling were differentially expressed between normal HSC and CP-CML LSC. These include FOXM1, 
CCNB1/2 and STIL. Other signalling pathways converge on these molecules and expression may also be driven 
by other factors. For example, FOXM1 is a transcription factor with a role in cell proliferation and DNA repair, 
and in addition to Hh signalling, is regulated by input from various other pathways at a transcriptional level e.g. 
FOXO3A48, p53 and E2F149. STIL is involved in haemopoiesis and is regulated by various factors including GATA 
transcription factors50.
Zhao et al. and Dierks et al. clearly demonstrated that Smo inhibition in murine models of CML, either by 
genetic knock-out or by pharmacological inhibition with the non-clinical SMO inhibitor cyclopamine, potently 
inhibited the propagation of leukaemic cells and the reconstitution of disease in secondary transplant models 
leading to prolonged survival of transplant recipients24,27. Both groups also provided evidence of a similar effect 
in primary BC-CML cells in in vitro surrogate assays of clonogenic potency. More recently, Sadarangani et al. 
demonstrated that BC-CML LSC could be targeted using the SMO antagonist PF-04449913, and this acted syn-
ergistically with BCR-ABL inhibition to reduce BC-CML LSC survival and self-renewal, likely through down-
regulation of GLI245. Further recent studies have shown evidence for efficacy of dasatinib in combination with 
the SMO inhibitor GDC-0449 in BCR-ABL+ cell lines51 and ponatinib in combination with GDC-0449 in resist-
ant BCR-ABL+ cells expressing the T315I mutation52. From a clinical perspective, treating BC-CML and T315I 
-mutated CML remain important, but the advent of TKI therapy has allowed increasing numbers of patients to 
remain in CP indefinitely with relatively low risk of progression albeit at the price of continuous treatment, due 
in part to LSC persistence. Therefore there is a clear imperative to attempt to find more effective ways of targeting 
the malignant LSC at an earlier stage (i.e. CP-CML) prior to progression to advanced phase.
Here we provide evidence that targeting the Hh pathway using the clinically investigated SMO inhib-
itor LDE225 in combination with nilotinib is an effective strategy for targeting CP-CML LSC. We show that 
LDE225 + nilotinib results in reduced CFC re-plating capacity and LTC-IC potential, reduced engraftment of 
human CD34+ CML cells in immunodeficient mice and prolonged survival with reduced leukaemogenic poten-
tial in the transgenic Scl-tTa-BCR-ABL mouse model that is more representative of CP-CML. It is noteworthy that 
LDE225 selectively inhibits self-renewal of LSC with minimal effects on apoptosis and proliferation of committed 
progenitors, differentiating this agent from most other anti-leukaemia agents currently being tested. Our obser-
vation of primary cilia in both normal haemopoietic and leukaemic cells indicates that the Hh pathway may be 
acting via canonical signaling, although we cannot exclude that activation of downstream Hh signaling results 
from cross-talk between the Hh pathway and other self-renewal pathways25. In contrast to Dierks et al. who 
indicated that Hh pathway activation in BCR-ABL+ leukaemogenesis was via upregulation of SMO27, we found 
no evidence for this; with no increased expression of SMO at the gene or protein level in CP-CML. A possible 
reason for this is the different in vitro cell models and murine models used in addition to the different stages of 
CML under analysis. The ability of the SMO inhibitor LDE225 in combination with nilotinib to selectively target 
quiescent LSC is an important step in the development of LSC-directed therapies.
This is the first study to demonstrate that a SMO inhibitor suitable for clinical development has efficacy against 
CP-CML LSC both in vitro and in vivo, and provided preclinical support for clinical trials of LDE225 (Sonidegib) 
in combination with nilotinib in CP-CML patients who have failed prior therapy with other BCR-ABL 
tyrosine-kinase inhibitors (NCT01456676). However, as with a similar study combining a SMO inhibitor with 
dasatinib53, this clinical trial has terminated early due to lack of efficacy and tolerability54. The heterogeneity of Hh 
pathway gene expression and response to the SMO inhibitor LDE225 indicate that further studies are required to 
identify if there are particular subpopulations of patients more likely to benefit from combination therapy with 
a SMO inhibitor ± TKI and if there are downstream Hh pathway targets amenable to therapy with less toxicity.
Materials and Methods
Patient samples. Patient samples were peripheral blood or leukapheresis products taken at time of diag-
nosis with CML, with written informed consent obtained from all subjects in accordance with the Declaration 
of Helsinki, and approval of the Greater Glasgow and Clyde National Health Service Trust Institutional Review 
Board. Samples were enriched for CD34+ cells using the CliniMACS (Miltenyi Biotec) immunomagnetic beads 
system. Samples enriched for CD34+ cells were cryopreserved in 10% DMSO (Sigma-Aldrich) and 5% human 
albumin solution (Baxter Healthcare) in liquid nitrogen until required.
Primary cell culture. Cryopreserved primary CD34+ cells were recovered from liquid nitrogen as previously 
described10 and cultured overnight in a humidified incubator at 37 °C with 5% CO2 in SFM consisting of Iscove 
Modified Dulbecco Medium (Sigma-Aldrich) containing serum substitute (bovine serum albumin, insulin, 
transferrin [BIT]; Stem Cell Technologies), 0.1 μ M 2-mercaptoethanol (Sigma-Aldrich), penicillin-streptomycin, 
L-glutamine plus a high concentration growth factor (5GF) cocktail containing 100 ng/mL Flt3-ligand (Flt3-L), 
100 ng/mL stem cell factor (SCF), 20 ng/mL interleukin-3 (IL-3), 20 ng/mL IL-6 (Stem Cell Technologies) and 
20 ng/mL granulocyte-colony stimulating factor (G-CSF; Chugai Pharma) to maximize cell recovery. In selected 
experiments following overnight culture, cells were washed and cultured in SFM supplemented with 5GF cock-
tail, a physiological growth factor cocktail comprising 5 ng/mL Flt3-L, 5 ng/mL SCF, 1 ng/mL IL-3, 1 ng/mL IL-6 
and 1 ng/mL G-CSF (LGF) or SFM alone.
Reagents. LDE225 and nilotinib were kindly provided by Novartis Pharma. Ten millimolar stock solutions 
were prepared in DMSO (Sigma-Aldrich) and stored at − 20 °C. Dilutions of these stock solutions were freshly 
prepared for each experiment in appropriate cell culture media.
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Immunocytochemistry of paraffin-embedded, decalcified bone marrow trephines. Sections 
were mounted on glass slides, deparaffinised and rehydrated. Antigen retrieval was performed according to 
standard protocols. Sections were subsequently washed in PBS/Tween before serially adding antibodies and 
incubating for 1 h at room temperature (RT) or overnight at 4 °C. Supplementary Table 2 shows antibody details. 
Slides were mounted with DAPI (Invitrogen) and visualised with a confocal scanning microscope (Zeiss). Positive 
and negative controls were included with each experiment; settings were adjusted between samples.
Immunocytochemistry of paraffin-embedded, decalcified bone marrow trephines. Single anti-
body detection was accomplished using a Leica Bond III immunostainer. All antibodies were optimised prior to 
use on control material as specified by product datasheet. Supplementary Table 3 shows antibodies details.
Fluorescence activated cell sorting (FACS) strategy. Cells were either used as a bulk CD34+ enriched 
population or stained with lineage cocktail, anti-CD34, CD38, CD90, CD45RA and CD123 (all BD Biosciences) 
prior to sorting into HSC (lin−CD34+CD38−CD90+), CMP (lin−CD34+CD38+CD123+CD45RA−), GMP 
(lin−CD34+CD38+ CD123+CD45RA+) MEP (lin−CD34+CD38+CD123−CD45RA−) populations using a FACS 
Aria flow cytometer (BD Biosciences).
Proliferation/apoptosis/cell cycle analysis. CD34+ CP-CML cells were seeded in SFM 
alone ± LDE225 ± nilotinib and cultured for 24–72 h prior to assessment. Proliferation was measured using 
colorimetric assessment of BrDU incorporation (Roche). Proportion of viable cells versus those in early and 
late apoptosis was assessed by flow cytometry using annexin V–FITC and 7-amino-actinomycin D (7-AAD, 
Via-Probe solution; both from BD Biosciences) according to the manufacturer’s instructions. Cell cycle status 
was assessed as previously described using Ki67 (FITC; BD Biosciences) expression and 7-AAD incorporation55.
CFC assay/re-plating assay. CD34+ CP-CML cells were seeded in SFM ± LDE225 ± nilotinib and cultured 
for 72 h then washed three times, inoculated at a concentration of 4 × 103/ml into methylcellulose supplemented 
with growth factors (Methocult H4034; Stem Cell Technologies) and cultured in duplicate for 14d prior to col-
ony assessment. Following assessment, at least 20 colonies (granulocyte-erythroid-megakaryocyte-macrophage 
[GEMM] or granulocyte macrophage [GM]) colonies were plucked from each experimental arm and serially 
re-dispersed in Methocult with secondary and tertiary colony formation assessed after 7d intervals.
LTC-IC assay. Primary CD34+ normal and CP-CML cells were cultured in SFM ± LDE225 ± nilotinib for 
72 h. Following this, they were thoroughly washed and inoculated into pre-prepared long term cultures com-
prising a stromal feeder layer (a 1:1 mix of irradiated (80 Gy) SL/SL and M210B4 murine fibroblasts) in long 
term myeloid culture medium (MyeloCult supplemented with hydrocortisone; both Stem Cell Technologies) as 
previously described35. These cultures were maintained for 5 weeks with 50% media changes performed weekly. 
Following this, the contents of the wells were harvested and cells counted prior to seeding into Methocult to per-
form CFC assays as described above.
Long term stromal co-culture. CD34+ CP-CML cells were inoculated directly into pre-prepared stromal 
co-cultures, as described above, in the presence of LDE225 ± nilotinib. Cultures were maintained for 5 weeks 
with 80% media changes and addition of fresh drug weekly. Co-cultures were examined weekly by microscopy 
to ensure that the stromal layer remained morphologically normal and adherent. After 5 weeks, CFC assays were 
performed as described.
Assessment of gene expression by qRT-PCR. RNA extraction was performed using the Qiagen RNEasy 
Minikit according to the manufacturer’s instructions. Reverse transcription was performed using the high capac-
ity cDNA synthesis kit (Applied Biosystems). Quantitative RT-PCR was performed using the Taqman system 
on a Taqman 7900 instrument (Applied Biosystems). Gene expression was determined relative to GAPDH and 
expressed either as 2−ΔCt or compared to an untreated calibrator (2−ΔΔCt)56.
Assessment of gene expression in human and murine haemopoietic stem and progenitor cell 
subpopulations using Fluidigm Biomark. RNA was extracted from human and murine subpopula-
tions, reverse transcribed, and 14 cycles of gene-specific amplification performed using the Applied Biosystem 
pre-amplification kit with relevant Taqman probe sets (Supplementary Tables 4 and 5). Following amplification 
the resultant products were loaded in triplicate onto pre-primed 48 × 48 Fluidigm microfluidic dynamic arrays 
and analysed according to the manufacturer’s instructions. Gene expression was determined relative to GAPDH, 
HRPT1 or B2m.
Fluorescence in situ hybridisation (FISH). Fluorescence in situ hybridization was performed with the 
LS1 BCR-ABL Dual Color FISH probe (Abbott Diagnostics) according to the manufacturer’s instructions.
Lentiviral ShRNA construction, production and transfection of primary CD34+ CP-CML 
cells. A hairpin against human SMO mRNA in a PLKO.1 plasmid was obtained from Open Biosystems 
(TRCN0000014367); (CCGGCCTGACTGTGAGATCAAGAATCTCGAGATTCTTGATCTCACAGTCA 
GGTTTTT), and was excised using Nde and SpeI restriction enzyme digestion and ligated into a PLKO.1-GFP 
tagged plasmid. PLKO.1-scram-GFP plasmid containing a non-targeting hairpin sequence acted as a control. 
HEK-293 cells were transfected with PLKO.1-Δ SMO-GFP or PLKO.1-scram-GFP control plasmid in the pres-
ence of HIV-1, VSV-g accessory plasmids and CaCl2. Virus laden supernatant was collected (DMEM supple-
mented with 20% FCS)57,58. For primary cell transfection, CD34+ CP-CML cells were removed from cryogenic 
storage and cultured overnight in SFM + 5GF. Thereafter, primary CD34+ CP-CML cells were spinoculated in 
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freshly collected viral medium supplemented with Transdux™ (Cambridge Bioscience) at 400 × g for 90 mins 
at 24 h, 48 h and 72 h for a total of three rounds of transduction. Following this, CD34+ cells were washed and 
re-suspended in SFM + 5GF for 48 h prior to sorting. GFP+ cells were FACS sorted for subsequent RNA isolation. 
qRT-PCR was performed to assess relative abundance of Hh related mRNA.
Human CD34+ Cell Engraftment in Immunodeficient Mice. The NSG mouse model (Jackson 
Laboratory) was used to assay human HSC/LSCs with in vivo engraftment capacity (SCID-repopulating cells or 
SRC). CD34+ CP-CML cells (2 × 106 cells/ mouse) or cord blood (CB) CD34+ cells (1 × 105 cells/mouse) were 
cultured for 72 h without drug (control), or with LDE225 (10 nM) ± nilotinib (5 μ M), at 37 °C in a humidified 
atmosphere with 5% CO2 in SFM + GFs as previously described59. Cells were harvested, washed and transplanted 
via tail vein injection into sublethally irradiated (300 cGy) 8 week old NSG mice. Mice were euthanised after 
6 weeks and marrow contents of femurs were obtained. To assess human cell engraftment, cells were labeled 
with anti-human CD45, CD34 and CD33 antibody prior to analysis by flow cytometry. Human CD45+ cells 
were selected using immunomagnetic columns and analyzed in CFC assays and by FISH and qRT-PCR for the 
BCR-ABL gene rearrangement. All experimental procedures were carried out in accordance with federal guide-
lines and protocols approved by City of Hope’s Institutional Animal Care and Use Committee.
Analysis of Transgenic EGFP+/SCLtTA/TRE-BCR-ABL Mice. The transgenic EGFP+/SCLtTA/
TRE-BCR-ABL mouse model was used to investigate the effect of LDE225 treatment on CML LSC in vivo. 
Scl-tTa-BCR-ABL mice in the FVB/N background were crossed with transgenic GFP-expressing mice (FVB.
Cg-Tg [ACTB-EGFP] B5Nagy/J; The Jackson Laboratory)31. Bone marrow cells were obtained 4 weeks post 
induction, GFP+ cells were selected by flow cytometry and transplanted by tail vein injection (106 cells/mouse) 
into wild-type FVB/N recipient mice, irradiated at 900 cGy, generating a large cohort of mice with similar time of 
onset of leukemia. Blood samples obtained 4 weeks post transplantation confirmed a neutrophilic leukocytosis 
in recipient mice. Mice were treated with nilotinib (50 mg/kg by gavage, daily), LDE225 (80 mg/kg by gavage, 
daily), LDE225 + nilotinib, or with vehicle alone (control). After 3 weeks of treatment, animals were eutha-
nised and marrow content of femurs and tibiae, spleen cells and blood obtained. Total white cell count (WCC), 
GFP-expressing WCC, myeloid cells, and GFP+ progenitors and stem cells were measured by flow cytometry. 
Survival was assessed in a subset of mice for 120d post discontinuation of treatment. Spleen and BM cells from 
a subset of mice in each arm were pooled and 5 × 106 cells/mouse (8 mice/condition) were transplanted into 
wild-type FVB/N recipient mice irradiated at 900 cGy. Engraftment was monitored by drawing peripheral blood 
(PB) every 4 weeks. The percentage of GFP+ cells in PB was analyzed by flow cytometry.
Statistical analysis. Statistical analyses were performed using the Student’s T-test or ANOVA as necessary 
P ≤ 0.05 was considered statistically significant.
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